临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 863127-77-9

Dasatinib Monohydrate

中文名称: 达沙替尼(一水合物)
CAS号:863127-77-9
分子式: C22H28ClN7O3S 分子量: 506.02
产品形式: Monohydrate
研发状态: Recruiting
研发用途: Recent HIV-1 Infection
研究机构: Eva Bonfill; Institut d''Investigacions Biomèdiques August Pi i Sunyer
研发日期: January 26 2024
研发阶段: Phase 2
Dasatinib Monohydrate (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

CAS: 863031-21-4

Azilsartan Medoxomil

中文名称:阿齐沙坦奥美沙坦酯
CAS号:863031-21-4
分子式: C30H24N4O8 分子量: 568.53
产品形式: free base
研发状态: Completed
研发用途: Healthy Volunteer
研究机构: Takeda
研发日期: November 20 2015
研发阶段: Phase 1
Azilsartan Medoxomil (TAK-491) is a potent angiotensin II type 1 (AT1) receptor antagonist, inhibits the RAAS, with an IC50 of 2.6 nM, exhibits >10,000-fold selectivity over AT2.

CAS: 862507-23-1

Ralimetinib (LY2228820) dimesylate

中文名称:5-[2-(叔丁基)-4-(4-氟苯基)-1H-咪唑-5-基]-3-(2,2-二甲基丙基)-3H-咪唑并[4,5-B]吡啶-2-胺甲磺酸盐
CAS号:862507-23-1
分子式: C24H29FN6.2CH4O3S 分子量: 612.74
产品形式: dimesylate
研发状态: Completed
研发用途: Advanced Cancer; Metastatic Cancer; Colorectal Cancer; Non-small Cell Lung Cancer
研究机构: Eli Lilly and Company
研发日期: August 10 2016
研发阶段: Phase 1
Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.

CAS: 86227-47-6

Eicosapentaenoic acid ethyl ester

中文名称:全顺-5,8,11,14,17-二十碳五烯酸乙酯
CAS号:86227-47-6
分子式: C22H34O2 分子量: 330.50
产品形式: Free Base
研发状态: Completed
研发用途: Colorectal Adenoma; Colorectal Cancer; Endoscopic Surgery; Eicosapentaenoic Acid; Gastrointestinal Microbiome
研究机构: Massachusetts General Hospital; National Institutes of Health (NIH)
研发日期: December 9 2020
研发阶段: Phase 1 : Phase 2
Eicosapentaenoic acid ethyl ester (AMR101, EPA ethyl ester, Ethyl eicosapentaenoate) is an omega-3 fatty acid agent that significantly reduces the triglyceride (TG) levels and improves other lipid parameters without significantly increasing the low-density lipoprotein (LDL) cholesterol levels.

CAS: 86050-77-3

Gadopentetate Dimeglumine

中文名称: 钆喷酸葡胺
CAS号:86050-77-3
分子式: C14H18GdN3O10.2C7H17NO5.2H 分子量: 938.00
产品形式: dimeglumine salt
研发状态: Active not recruiting
研发用途: Pancreatic Adenocarcinoma
研究机构: Columbia University
研发日期: Nov-13
研发阶段: Not Applicable
Gadopentetate Dimeglumine (Gadopentetic acid dimeglumine, Gd-DTPA, Meglumine gadopentetate), a complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid, is an extracellular intravenous contrast agent used in magnetic resonance imaging.

CAS: 860352-01-8

AZD7762

中文名称:3-[(氨基羰基)氨基]-5-(3-氟苯基)-N-(3S)-3-哌啶基-2-噻吩羧胺
CAS号:860352-01-8
分子式: C17H19FN4O2S 分子量: 362.42
产品形式: free base
研发状态: Terminated
研发用途: Cancer; Solid Tumors; Advanced Solid Malignancies
研究机构: AstraZeneca
研发日期: Jul-09
研发阶段: Phase 1
AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.